+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating UBT251, a new medication, in adults with type 2 diabetes to determine its effectiveness and safety. The study compares UBT251 to a placebo and also includes a comparison to semaglutide, an existing treatment for type 2 diabetes. The trial is designed as a phase 2 study to find the appropriate dose and assess treatment impact on blood sugar control. Participants will be randomly assigned to one of four groups receiving UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Each participant will receive their assigned treatment once weekly by subcutaneous injection. The study includes a treatment period lasting up to 40 weeks, with evaluations at various points including weeks 16, 28, and 40. Throughout the study, participants will undergo regular assessments such as measuring glycated hemoglobin HbA1c to track blood sugar levels, body weight, insulin resistance, blood pressure, cholesterol, and kidney function. Safety will be monitored by recording treatment-emergent adverse events up to 46 weeks. The total participation time covers baseline, treatment, and follow-up visits to evaluate the study outcomes comprehensively.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
S

Actively Recruiting

Healthy Volunteer

The GEROS Project is designed to develop and implement a Service-Learning program that combines Comprehensive Geriatric Assessment CGA and health promotion for older adults aged 60 and above. It involves university students from various health-related fields and aims to foster intergenerational learning and community engagement. The study follows a non-experimental mixed-method design and focuses on evaluating frailty, intrinsic capacity, quality of life, and other health indicators in participating older adults. Participants will receive a series of three sessions at the University of Vic - Central University of Catalonia, where students supervised by health professionals conduct CGA evaluations. Following the assessment, users receive a report with their CGA results along with personalized health education and recommendations. The program integrates practical student training with real-world health promotion for older adults. During the study, researchers will assess frailty and quality of life at baseline, and measure satisfaction and self-perceived knowledge and skills of both students and older adult participants after the intervention sessions. Data will be collected through questionnaires and recorded using REDCap. The study supports active aging and aligns with global health and equality goals, with total participation spanning up to 2-4 weeks after intervention.

Age: 60Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating the relationship between motor skills and sensory processing in children aged 4 to 11 years who have either typical or atypical neurodevelopment, including Autism Spectrum Disorder ASD, Attention Deficit Hyperactivity Disorder ADHD, and Developmental Coordination Disorder DCD. This cross-sectional observational case-control study aims to better understand how these developmental disorders affect childrens growth, learning, communication, behavior, social skills, and motor abilities. The study follows STROBE guidelines and is conducted by the University of Vic - Central University of Catalonia, with ethical approvals in place to protect participants and their data. The study includes two groups children with typical neurodevelopment and children with atypical neurodevelopment diagnosed with ASD, ADHD, or DCD. Participants will be recruited from local communities and specialized centers. Motor skills will be assessed using the Movement Assessment Battery for Children-Second Edition MABC-2, while sensory processing will be evaluated through the Short Sensory Profile-2 SSP-2 caregiver questionnaire. Recruitment will occur from December 2024, with assessments and data collection performed according to the study protocol. Participants will be involved in assessments of motor development and sensory processing, including video-recorded sessions for motor skills evaluation. Researchers will collect demographic and developmental information from parents or guardians. The main outcome measured is motor skill development within one month of enrollment, with sensory processing also assessed during this time. Confidentiality and data protection are ensured, and participants may withdraw at any time. The study is expected to provide insights to help tailor future clinical and educational interventions for children with developmental differences.

Age: 4Years - 11YearsAll Genders
1 location
I

Actively Recruiting

Researchers are evaluating an integrated home care program called ADMIT for older adults aged 70 or more who live at home and face complex health and social needs. The study aims to see if this multi-component intervention, which uses technology and coordinated care, can increase the percentage of days these individuals spend at home compared to usual care. Additional goals include reducing health crises, improving quality of life for patients and their caregivers, and assessing the programs cost-effectiveness and overall experience. Participants will be randomly assigned to either receive usual care or the ADMIT program, which is co-created by professionals, patients, and caregivers. The ADMIT program involves proactive candidate detection from health and social services, assignment of reference professionals from both sectors, shared diagnosis and individualized care plans, and ongoing shared follow-up. A technological platform supports communication and information sharing among all parties, with optional use of sensors and robotic devices to assist home care. During the six-month intervention, researchers will track the percentage of days participants spend at home, monitor health and social crises, and gather feedback on experiences from patients, caregivers, and professionals. The study uses mixed methods to evaluate effectiveness, safety, and cost-utility in real-world settings, with an overall goal to support aging individuals in their homes while improving care quality and system sustainability.

Age: 70Years +All GendersPhase Not Applicable
8 locations
D

Actively Recruiting

Researchers are evaluating a digital health program designed to improve bladder health and manage urinary incontinence in adults aged 50 and over. This study involves co-creating a new module within the approved Keep-on-Keep-up KOKU app, developed with input from users, health professionals, and experts. The research includes a randomized controlled trial to test the programs feasibility and acceptability using behavior change techniques and addressing active and healthy aging policies. The study is organized into several phases, starting with protocol preparation and expert consultations, followed by multiple focus groups in Lithuania, Spain, and the UK to co-create the app module. After development, a 12-week intervention will be conducted with at least 120 participants across three countries, randomly assigned to either the KOKU Bladder app group or a control group receiving recommendations for self-managing urinary symptoms. Both groups will be assessed using qualitative and quantitative methods. Participants will engage in the trial for up to three years, during which their urinary incontinence symptoms, life impact, satisfaction with treatment, and bladder health will be regularly evaluated using questionnaires and tests such as the Incontinence Impact Questionnaire-7 and the International Prostate Symptom Score. Data collection includes thematic analysis of qualitative feedback and measurement of symptom severity and patient impressions. Safety and ethical considerations are integrated throughout, with plans for open communication and dissemination of results.

Age: 50Years - 100YearsAll GendersPhase Not Applicable
4 locations